Hyperkinetic Movement Disorders after Thalamic Lesions
Objective: To describe delayed hyperkinetic movement disorder after a thalamic lesion. Background: Lesions in the basal ganglia circuit can cause abnormal movement disorders. After thalamic…Hemiparkinsonism Due to Diencephalic Lesion with 24 Years of Levodopa Response and Only Mild Dyskinesia
Objective: To present a case of a long-standing hemiparkinsonism due to cerebral lesion with a continuous response to a stable dose of levodopa with only…Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?
Objective: Evaluate delayed release/extended release amantadine (AMT DR/ER) capsules for motor complications in patients meeting 5-2-1 criteria for device-aided therapies (DAT) in advanced Parkinson disease.…Early-onset vs. Late-onset Parkinson’s disease
Objective: To determine the clinical and therapeutic peculiarities that distinguish Early onset Parkinson’s disease (EOPD) from late onset Parkinson’s disease (LOPD). Background: Age is the…Amantadine DR/ER-Related Reduction in OFF and Dyskinesia Improved Patient-Rated Interference with Activities and Social Interactions
Objective: Evaluate dyskinesia and OFF interference with activities and experiences for persons with Parkinson disease (PWPD), and mitigation with treatment Background: OFF and Dyskinesia remain…Risk factors for the onset of dyskinesia in patients with Parkinson’s disease exhibiting wearing-off phenomena: A 1-year observational study in Japan (J-FIRST)
Objective: To investigate the risk factors for the onset of dyskinesia in patients with Parkinson's disease (PD) exhibiting wearing-off phenomena. Background: Dyskinesia occurs during long-term…Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease
Objective: Utilize clinical trial data to analyze amantadine delayed release/extended release (AMT DR/ER) capsules as an early add-on for OFF and dyskinesia in people with…The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson’s disease
Objective: The aim of our study is to search for genetic risk factors for the development of motor side effects of dopaminergic therapy, such as…SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models
Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…Gut dysbiosis in Parkinson’s disease with motor complications
Objective: We aimed to identify gut dysbiosis in Parkinson's disease patients with motor complications. Background: Recently, several evidences suggest that the gut microbiota is associated…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 44
- Next Page »